[go: up one dir, main page]

IN2014CN02964A - - Google Patents

Info

Publication number
IN2014CN02964A
IN2014CN02964A IN2964CHN2014A IN2014CN02964A IN 2014CN02964 A IN2014CN02964 A IN 2014CN02964A IN 2964CHN2014 A IN2964CHN2014 A IN 2964CHN2014A IN 2014CN02964 A IN2014CN02964 A IN 2014CN02964A
Authority
IN
India
Prior art keywords
recombinant host
host cells
recombinant
dolichyl
host cell
Prior art date
Application number
Inventor
Byung Kwon Choi
Natarajan Sethuraman
Stephen R Hamilton
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of IN2014CN02964A publication Critical patent/IN2014CN02964A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/395—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/52—Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

NNMethods for increasing the yield and glycosylation site occupancy of paucimannose or complex glycans of recombinant glycoproteins produced in a recombinant host cell lacking dolichyl P Man:Man5GlcNAc2 PP dolichyl alpha 1 3 mannosyltransferase (Alg3p) activity are disclosed. In particular recombinant host cells are provided that comprise a disruption of the expression of an OS 9 family gene in the host cell. These recombinant host cells may then be used for producing recombinant glycoproteins. In further embodiments the recombinant host cells further overexpress at least one heterologous single subunit oligosaccharyltransferase which in particular embodiments is capable of functionally suppressing the lethal phenotype of a mutation of at least one essential protein of the yeast oligosaccharyltransferase (OTase) complex.
IN2964CHN2014 2011-10-28 2012-10-23 IN2014CN02964A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161552720P 2011-10-28 2011-10-28
US201261679212P 2012-08-03 2012-08-03
PCT/US2012/061428 WO2013062939A2 (en) 2011-10-28 2012-10-23 Methods for increasing n-glycan occupancy and reducing production of hybrid n-glycans in pichia pastoris strains lacking alg3 expression

Publications (1)

Publication Number Publication Date
IN2014CN02964A true IN2014CN02964A (en) 2015-07-03

Family

ID=48168764

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2964CHN2014 IN2014CN02964A (en) 2011-10-28 2012-10-23

Country Status (9)

Country Link
US (1) US9428784B2 (en)
EP (1) EP2771479B1 (en)
JP (1) JP2015502144A (en)
KR (1) KR20140091017A (en)
CN (1) CN104471053A (en)
AU (1) AU2012329090A1 (en)
CA (1) CA2853338A1 (en)
IN (1) IN2014CN02964A (en)
WO (1) WO2013062939A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104471053A (en) 2011-10-28 2015-03-25 默沙东公司 Methods for increasing N-glycan occupancy and reducing production of hybrid N-glycans in Pichia pastoris strains lacking ALG3 expression
EP2956158A4 (en) * 2013-02-13 2016-10-05 Merck Sharp & Dohme METHODS FOR INCREASING OCCUPANCY OF N-GLYCANS AND REDUCING HYBRID N-GLYCAN PRODUCTION IN PICHIA PASTORIS STRAINS THAT DO NOT EXPRESS ALG3
HRP20190218T1 (en) 2013-07-10 2019-03-22 Glykos Finland Oy Production of glycoproteins with increased N-glycolysis site occupancy
CN106062203B (en) 2013-10-11 2020-08-07 葛兰素史密丝克莱恩生物有限公司 Method for host cell modification
CN108064266A (en) 2014-07-21 2018-05-22 格利科斯芬兰公司 Preparation of glycoproteins with mammalian-like N-glycans in filamentous fungi
WO2016140925A1 (en) 2015-03-02 2016-09-09 Synthetic Genomics, Inc. Regulatory elements from labyrinthulomycetes microorganisms
WO2017025586A1 (en) * 2015-08-13 2017-02-16 Glykos Finland Oy Regulatory protein deficient trichoderma cells and methods of use thereof
WO2018085273A1 (en) * 2016-11-01 2018-05-11 Synthetic Genomics, Inc. Expression of modified glycoproteins and glycopeptides
US10633454B2 (en) 2016-11-01 2020-04-28 Conagen Inc. Expression of modified glycoproteins and glycopeptides
CN111108211A (en) * 2017-06-30 2020-05-05 利玛泰克生物制品公司 Engineered and fully-functional customized glycoproteins
EP4219537A4 (en) * 2020-09-22 2025-03-26 Jecho Laboratories, Inc. Glycosylation-modified erythopoietin and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7598055B2 (en) * 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
US7863020B2 (en) * 2000-06-28 2011-01-04 Glycofi, Inc. Production of sialylated N-glycans in lower eukaryotes
US7332299B2 (en) * 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
CN102858949B (en) * 2010-02-24 2016-07-06 默沙东公司 Methods for increasing N-glycosylation site occupancy on therapeutic glycoproteins produced in Pichia pastoris
CN104471053A (en) 2011-10-28 2015-03-25 默沙东公司 Methods for increasing N-glycan occupancy and reducing production of hybrid N-glycans in Pichia pastoris strains lacking ALG3 expression
EP2956158A4 (en) * 2013-02-13 2016-10-05 Merck Sharp & Dohme METHODS FOR INCREASING OCCUPANCY OF N-GLYCANS AND REDUCING HYBRID N-GLYCAN PRODUCTION IN PICHIA PASTORIS STRAINS THAT DO NOT EXPRESS ALG3

Also Published As

Publication number Publication date
CA2853338A1 (en) 2013-05-02
EP2771479A4 (en) 2015-08-05
AU2012329090A1 (en) 2014-05-01
US9428784B2 (en) 2016-08-30
JP2015502144A (en) 2015-01-22
CN104471053A (en) 2015-03-25
US20140329276A1 (en) 2014-11-06
WO2013062939A3 (en) 2014-09-25
EP2771479B1 (en) 2020-01-08
WO2013062939A2 (en) 2013-05-02
KR20140091017A (en) 2014-07-18
EP2771479A2 (en) 2014-09-03

Similar Documents

Publication Publication Date Title
IN2014CN02964A (en)
Loke et al. Emerging roles of protein mannosylation in inflammation and infection
PH12019550056A1 (en) Improved process for the production of fucosylated oligosaccharides
MX2013005853A (en) Fusion enzymes having n-acetylglucosaminyltransferase activity.
WO2004074458A3 (en) N-acetylglucosaminyltransferase iii expression in lower eukaryotes
AU2010291066A8 (en) Protein glycosylation
BR112016021857A2 (en) altered host cell pathway for enhanced ethanol production
JP2017060528A5 (en)
GB201115841D0 (en) Protein and method
SA112330816B1 (en) Protein expression
NZ743008A (en) Compositions and methods for internalizing enzymes
MX2009012747A (en) Recombinant protein production in avian ebxâ(rtm) cells.
MXPA04006357A (en) Methods to engineer mammalian-type carbohydrate structures.
BR112013018695A2 (en) isolated polypeptides, enzyme composition, isolated polynucleotides, nucleic acid construct or expression vector, recombinant host cell, methods for producing a cellobiohydrole activity polypeptide, and a protein, and for fermenting a cellulosic material, and processes for degrading a cellulosic material, and to synthesize a fermentation product
BR112017018149A2 (en) recombinant host cell, method for producing a recombinant protein of interest, expression system, and processes for making a stable protein formulation and for reducing esterase activity in a protein formulation.
WO2008112092A3 (en) Production of glycoproteins with modified fucosylation
Hoshida et al. N-glycosylation deficiency enhanced heterologous production of a Bacillus licheniformis thermostable α-amylase in Saccharomyces cerevisiae
EP4241854A3 (en) Lysosomal storage disease enzyme
JP2017502694A5 (en)
BR112012003609A2 (en) New protein which has beta-glucosidase activity, and its use
EA201390592A1 (en) ALLEYS 1-D-DEOXYXILULOUSO-5-PHOSPHATE SYNTHESIS RESPONSIBLE FOR STRENGTHENED TERPENES Biosynthesis
BR112017000696A2 (en) RECOMBINANT HUMAN CYTOMEGALOVIRUS (HCMV), ITS IMMUNOGENIC COMPOSITION, ITS USE, ISOLATED POLYNUCLEOTIDE, ISOLATED CELL AND METHOD OF PRODUCTION OF HCMV WITH DEFICIENCY PP71
MY186172A (en) Endogenous dnase activity to reduce dna content
WO2012173344A3 (en) Expression vector for animal cells including csp-b 5'-sar factor and method for producing recombinant proteins using same
GEP201606542B (en) Recombinant expression of soluble interferon